For example, alpelisib is currently in Phase III trials for treatment of PIK3CA driver mutations in cancers of the lung and other tissues [46], and a combination of dabrafenib and trametinib has clear efficacy in treatment of BRAF:V600E mutated non-small cell lung cancers [47]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.